Orforglipron research: studies, doses and safety
A daily GLP-1 pill approved in the US for adult weight management.
Also called: LY3502970, LY-3502970, OWL833, Foundayo.
Oral GLP-1 agonists · Nonpeptide GLP-1 receptor agonist · Evidence: Approved drug.
47 started registry studies identified; pivotal ATTAIN and ACHIEVE results support weight and glucose effects. Long-term rare harms remain uncertain.
Key studies
- First-in-human and formulation cohorts: Results are posted in ClinicalTrials.gov; selected primary endpoints and safety counts are shown. (source)
- Phase 1b: diabetes dose finding: Results are posted in ClinicalTrials.gov; selected primary endpoints and safety counts are shown. (source)
- Radiolabeled mass balance: Results are posted in ClinicalTrials.gov; selected primary endpoints and safety counts are shown. (source)
- Phase 2: diabetes dose finding: Results are posted in ClinicalTrials.gov; selected primary endpoints and safety counts are shown. (source)
- A Multiple Dose Study of LY3502970 in Healthy Participants: Results are posted in ClinicalTrials.gov; selected primary endpoints and safety counts are shown. (source)
- Phase 2: obesity dose finding: Results are posted in ClinicalTrials.gov; selected primary endpoints and safety counts are shown. (source)
Related to Orforglipron
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA Approves First New Molecular Entity Under National Priority Voucher Program, FDA · 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- Foundayo, European Medicines Agency · 2026
- Foundayo (orforglipron) tablets, FDA · 2026
- FOUNDAYO- orforglipron tablet, film coated, DailyMed · DailyMed · 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- UK first in Europe to authorise orforglipron for weight management and type 2 diabetes, MHRA · 2026
- Weight Loss Drugs: What athletes need to know about GLP-1s, USADA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.